UNLABELLED: We evaluated vitamin D status in HIV+ and HIV- postmenopausal African-American (AA) and Hispanic women. Most women (74-78%) had insufficient 25-hydroxyvitamin D (25OHD) levels, regardless of HIV status. 25OHD was lower in AA women and women lacking supplement use, providing support for screening and supplementation. Among HIV+ women, 25OHD was associated with current CD4 but not type of antiretroviral therapy. INTRODUCTION: To evaluate vitamin D status and factors associated with vitamin D deficiency and insufficiency in HIV-infected (HIV+) postmenopausal minority women. METHODS: In this cross-sectional study, 89 HIV+ and 95 HIV- postmenopausal women (33% AA and 67% Hispanic) underwent assessment of 25OHD, 1,25-dihydroxyvitamin D, parathyroid hormone, markers of bone turnover and bone mineral density by dual energy X-ray absorptiometry. RESULTS: The prevalence of low 25OHD did not differ by HIV status; the majority of both HIV+ and HIV- women (74-78%) had insufficient levels (<30 ng/ml). Regardless of HIV status, 25OHD was significantly lower in AA subjects, and higher in subjects who used both calcium and multivitamins. In HIV+ women on antiretroviral therapy (ART), 25OHD was directly associated with current CD4 count (r=0.32; p<0.01) independent of age, ethnicity, BMI, or history of AIDS-defining illness. No association was observed between 1,25(OH)(2)D and CD4 count or between serum 25OHD, 1,25(OH)(2)D or PTH and type of ART. CONCLUSIONS: In postmenopausal minority women, vitamin D deficiency was highly prevalent and associated with AA race and lack of supplement use, as well as lower current CD4 cell count. These results provide support for screening and repletion of vitamin D in HIV+ patients.
UNLABELLED: We evaluated vitamin D status in HIV+ and HIV- postmenopausal African-American (AA) and Hispanic women. Most women (74-78%) had insufficient 25-hydroxyvitamin D (25OHD) levels, regardless of HIV status. 25OHD was lower in AA women and women lacking supplement use, providing support for screening and supplementation. Among HIV+ women, 25OHD was associated with current CD4 but not type of antiretroviral therapy. INTRODUCTION: To evaluate vitamin D status and factors associated with vitamin Ddeficiency and insufficiency in HIV-infected (HIV+) postmenopausal minority women. METHODS: In this cross-sectional study, 89 HIV+ and 95 HIV- postmenopausal women (33% AA and 67% Hispanic) underwent assessment of 25OHD, 1,25-dihydroxyvitamin D, parathyroid hormone, markers of bone turnover and bone mineral density by dual energy X-ray absorptiometry. RESULTS: The prevalence of low 25OHD did not differ by HIV status; the majority of both HIV+ and HIV- women (74-78%) had insufficient levels (<30 ng/ml). Regardless of HIV status, 25OHD was significantly lower in AA subjects, and higher in subjects who used both calcium and multivitamins. In HIV+ women on antiretroviral therapy (ART), 25OHD was directly associated with current CD4 count (r=0.32; p<0.01) independent of age, ethnicity, BMI, or history of AIDS-defining illness. No association was observed between 1,25(OH)(2)D and CD4 count or between serum 25OHD, 1,25(OH)(2)D or PTH and type of ART. CONCLUSIONS: In postmenopausal minority women, vitamin D deficiency was highly prevalent and associated with AA race and lack of supplement use, as well as lower current CD4 cell count. These results provide support for screening and repletion of vitamin D in HIV+ patients.
Authors: Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Yungtai Lo; Robert S Klein Journal: AIDS Date: 2007-03-12 Impact factor: 4.177
Authors: Mario Cozzolino; Marcos Vidal; Maria Vittoria Arcidiacono; Pablo Tebas; Kevin E Yarasheski; Adriana S Dusso Journal: AIDS Date: 2003-03-07 Impact factor: 4.177
Authors: Michael T Yin; Don J McMahon; David C Ferris; Chiyuan A Zhang; Aimee Shu; Ronald Staron; Ivelisse Colon; Jeffrey Laurence; Jay F Dobkin; Scott M Hammer; Elizabeth Shane Journal: J Clin Endocrinol Metab Date: 2009-12-04 Impact factor: 5.958
Authors: Julia H Arnsten; Ruth Freeman; Andrea A Howard; Michelle Floris-Moore; Nanette Santoro; Ellie E Schoenbaum Journal: Clin Infect Dis Date: 2006-02-24 Impact factor: 9.079
Authors: Shanna Nesby-O'Dell; Kelley S Scanlon; Mary E Cogswell; Cathleen Gillespie; Bruce W Hollis; Anne C Looker; Chris Allen; Cindy Doughertly; Elaine W Gunter; Barbara A Bowman Journal: Am J Clin Nutr Date: 2002-07 Impact factor: 7.045
Authors: Michael F Holick; Rachael M Biancuzzo; Tai C Chen; Ellen K Klein; Azzie Young; Douglass Bibuld; Richard Reitz; Wael Salameh; Allen Ameri; Andrew D Tannenbaum Journal: J Clin Endocrinol Metab Date: 2007-12-18 Impact factor: 5.958
Authors: Lediya T Cheru; Charles F Saylor; Kathleen V Fitch; Sara E Looby; Michael Lu; Udo Hoffmann; Takara L Stanley; Janet Lo Journal: Antivir Ther Date: 2019
Authors: Saurabh Mehta; Ferdinand M Mugusi; Donna Spiegelman; Eduardo Villamor; Julia L Finkelstein; Ellen Hertzmark; Edward L Giovannucci; Gernard I Msamanga; Wafaie W Fawzi Journal: AIDS Patient Care STDS Date: 2011-09-14 Impact factor: 5.078
Authors: Vin Tangpricha; Suzanne E Judd; Thomas R Ziegler; Li Hao; Jessica A Alvarez; Anne M Fitzpatrick; Grace A McComsey; Allison Ross Eckard Journal: AIDS Res Hum Retroviruses Date: 2014-05-28 Impact factor: 2.205
Authors: Kelly I Stephens; Leon Rubinsztain; John Payan; Chris Rentsch; David Rimland; Vin Tangpricha Journal: Endocr Pract Date: 2015-12-18 Impact factor: 3.443
Authors: Audrey L French; Oluwatoyin M Adeyemi; Denis M Agniel; Charlesnika T Evans; Michael T Yin; Kathryn Anastos; Mardge H Cohen Journal: J Womens Health (Larchmt) Date: 2011-08-29 Impact factor: 2.681